DPP4 and neoplasm: Consistent with a key role for CD8+ T-cell immunity, the antitumor effect of anti–PD-1 therapy in the DPP4-reconstituted group was abolished by CD8+ T-cell depletion, resulting in renewed tumor growth (Fig. 4H; Supplementary Fig. S4H).